Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 9986724

Genetically modified non-human animals and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9982013

Readily isolated bispecific antibodies with native immunoglobulin format

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9968653

Angiopoietin-based interventions for treating cerebral malaria

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9968674

Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibo

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9951132

Anti-prokineticin receptor (PROKR) antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9950076

Maytansinoid derivatives, conjugates thereof, and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9951141

Antibody-drug conjugates, their preparation and their therapeutic use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9951127

Anti-ANGPTL3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9943594

Methods for the treatment of rheumatoid arthritis

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9938345

Human antibodies to PD-L1

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9938339

Method for treating an eye disease or disorder by administering an antibody that binds ang

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9932398

Restricted immunoglobulin heavy chain mice

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9926369

Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9914763

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9913461

Genetically modified mouse whose genome comprises a humanized CD274 gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9901083

Non-human animals having a humanized signal-regulatory protein gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9901082

Genetically modified non-human animals and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9890212

Antibodies to human GDF8

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884916

High affinity antibodies to human IL-6 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9840549

Fusion polypeptides capable of activating receptors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9840557

Anti-IL-25 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9827310

Anti-ErbB3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9795121

Humanized C3 animals

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9790273

Anti-HLA-B*27 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted